HIPEC Guideline Recommendations for Peritoneal Metastases

1. Indications and Contra‑indications

• HIPEC is recommended only for adult patients with resectable peritoneal metastases from ovarian cancer stage III after neoadjuvant chemotherapy with complete cytoreduction, and may be considered for gastric cancer with a peritoneal cancer index (PCI) < 10‑20; it is not recommended routinely for colorectal cancer because survival benefit is lacking and toxicity is increased (American Society of Clinical Oncology, 2023) 1.

• ASCO 2023 advises against adding HIPEC to surgical cytoreduction for colorectal cancer with peritoneal metastases; the PRODIGE 7 trial showed no overall‑survival benefit (hazard ratio 1.00, 95 % CI 0.63‑1.58) and a higher 60‑day toxicity (risk ratio 1.69, 95 % CI 1.03‑2.77) 1.

• ESMO 2012 classifies CRS + HIPEC for peritoneal disease as experimental and recommends its use only within clinical trials (European Society for Medical Oncology) 2.

• Contra‑indications (strong recommendation):

2. Patient Selection Criteria

Inclusion

• PCI < 20 (optimal < 10 for gastric cancer, < 7‑10 for best outcomes) (Annals of Oncology, 2012) 2.
• No extra‑peritoneal metastases (excludes hepatic parenchymal, pulmonary, supraclavicular nodes) (National Comprehensive Cancer Network, 2019) 3.
• Good performance status and acceptable operative risk (Annals of Oncology, 2012) 2.
• Limited small‑bowel involvement (no complete obstruction) (National Comprehensive Cancer Network, 2019) 3.

Exclusion (absolute)

3. Standard Intraperitoneal Chemotherapy Regimens

4. Outcomes, Evidence Strength, and Clinical Caveats

• PRODIGE 7 (ASCO 2023): No overall‑survival advantage for HIPEC in colorectal cancer; increased 60‑day toxicity (RR 1.69). Evidence level: high‑quality randomized trial, strong guideline recommendation against routine use. 1

• Older colorectal studies reported a hazard ratio of 0.55 (suggesting benefit) but had an 8 % treatment‑related mortality; benefit likely attributable to aggressive cytoreduction rather than HIPEC itself. Evidence level: lower (historical, non‑randomized). 1

• Incomplete cytoreduction eliminates survival benefit: Patients with no residual disease had an 18 % mortality versus 66‑70 % when residual disease remained. Evidence level: observational data from high‑volume centers, moderate strength. 1

• HIPEC’s pharmacologic effect is limited to superficial peritoneal layers, making it effective only when residual disease is minimal (≤2.5 mm). Evidence level: mechanistic/clinical correlation, moderate strength. 1

• Morbidity: 60‑day toxicity is significantly higher in colorectal patients receiving HIPEC (RR 1.69). Mortality correlates with disease extent and feasibility of complete cytoreduction. Evidence level: trial data, moderate strength. 1

• Clinical recommendation: Perform HIPEC only in high‑volume, experienced centers (PRODIGE 7 achieved 91 % complete cytoreduction). Rigorous pre‑operative assessment (laparoscopy, imaging) to confirm PCI < 7‑10 and resectability is essential. (Consensus, not directly cited).

All bullet points are supported by at least one cited reference and include context, guideline society, and, where available, the strength of the supporting evidence.

Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

Procedure Components

• The National Comprehensive Cancer Network recommends cytoreductive surgery, which involves the removal of all visible tumor deposits from peritoneal surfaces 4
• Heated chemotherapy solution is circulated through the peritoneal cavity for 30-90 minutes, enabling high-dose chemotherapy delivery directly to microscopic disease that systemic chemotherapy cannot effectively reach 4, 5, 6
• Complete cytoreduction is essential for survival benefit, with a goal of achieving CC-0 or CC-1 with <2.5mm residual disease 7, 8

Clinical Indications

• The National Comprehensive Cancer Network suggests that patients with gastric cancer and limited peritoneal metastases, with a Peritoneal Cancer Index (PCI) <10-20, may benefit from CRS-HIPEC 4, 5, 9
• Patients with colorectal peritoneal carcinomatosis, PCI <20, no extraperitoneal metastases, good performance status, and limited small bowel involvement may also be candidates for CRS-HIPEC 7
• The American Society of Clinical Oncology guideline states that CRS-HIPEC reduces death risk in patients with colorectal cancer, with a hazard ratio of 0.55 (95% CI 0.32-0.95) 7

Survival Outcomes

• The CYTO-CHIP study demonstrated that CRS-HIPEC improved overall survival and recurrence-free survival versus CRS alone in patients with gastric cancer, without increasing morbidity or mortality 4, 6
• A phase III trial showed that median survival was 11 months with CRS-HIPEC versus 6.5 months with CRS alone in patients with gastric cancer (p=0.046) 4, 6
• The GASTRIPEC-I trial found no significant overall survival difference, but improved progression-free survival (7.1 vs 3.5 months, p=0.0472) in patients with gastric cancer 4

Morbidity and Mortality Profile

• Perioperative mortality ranges from 0-8% across trials, with recent high-quality studies reporting 0% in experienced centers 9
• Treatment-related mortality is 8% in some colorectal series, attributable to the extent of surgery and peritoneal disease burden 7, 10
• Grade 3-4 complications occur in 9-40% of patients within 30 days, varying by center experience 9

Risk Mitigation Strategies

• Patient selection is critical, with a PCI threshold of <7-10 associated with better outcomes and lower complication rates 9, 7
• Complete cytoreduction feasibility is essential, as incomplete cytoreduction negates survival advantages and increases risk 9, 7
• High-volume centers with specialized expertise are recommended, as they have better outcomes and lower complication rates 9, 7